These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15578396)

  • 1. Prediction of relapse following treatment for hepatitis C: is whole blood more than the sum of its parts?
    Shire N; Koziel MJ
    Clin Infect Dis; 2004 Dec; 39(12):1761-3. PubMed ID: 15578396
    [No Abstract]   [Full Text] [Related]  

  • 2. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
    Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
    Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HCV-RNA quantity of the serum].
    Sasaki Y; Hige S; Nagasaka A; Matsushima T
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):965-8. PubMed ID: 7563911
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute hepatitis C: prevention and treatment.
    Ozaras R; Tahan V
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):351-61. PubMed ID: 19344247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
    Ogata K; Kashiwagi T; Iwahashi J; Hara K; Honda H; Ide T; Kumashiro R; Kohara M; Sata M; Watanabe H; Hamada N
    Arch Virol; 2008; 153(8):1575-9. PubMed ID: 18592133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored treatment for hepatitis C.
    Berg T
    Clin Liver Dis; 2008 Aug; 12(3):507-28, vii-viii. PubMed ID: 18625426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical modeling of HCV infection and treatment.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 9. Viral kinetics in hepatitis C.
    Lutchman G; Hoofnagle JH
    Hepatology; 2003 Jun; 37(6):1257-9. PubMed ID: 12774002
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C: changing genotype distribution with important implications for patient management.
    van Soest H; Boland GJ; van Erpecum KJ
    Neth J Med; 2006 Apr; 64(4):96-9. PubMed ID: 16609154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of hepatitis C virus RNA detection in plasma, whole blood and peripheral blood mononuclear cells of patients with occult hepatitis C virus infection.
    Carreño V; Castillo I; Bartolomé J; Rodríguez-Iñigo E; Ortiz-Movilla N; de Lucas S; Pardo M
    J Clin Virol; 2004 Dec; 31(4):312-3. PubMed ID: 15494276
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of hepatitis C. Different modalities based on viral genotype].
    Pariente A
    Rev Prat; 2003 Jun; 53(11):1175-6. PubMed ID: 15185639
    [No Abstract]   [Full Text] [Related]  

  • 14. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
    Shedlofsky SI
    Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occult hepatitis C: how convincing are the current data?
    Welker MW; Zeuzem S
    Hepatology; 2009 Feb; 49(2):665-75. PubMed ID: 19105211
    [No Abstract]   [Full Text] [Related]  

  • 17. Prisons, prisoners, and hepatitis C.
    Ferguson L; Batey R
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1184-6. PubMed ID: 20594243
    [No Abstract]   [Full Text] [Related]  

  • 18. Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy.
    Januszkiewicz-Lewandowska D; Wysocki J; Pernak M; Nowicka K; Zawada M; Rembowska J; Lewandowski K; Mańkowski P; Nowak J
    Jpn J Infect Dis; 2007 Feb; 60(1):29-32. PubMed ID: 17314422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatitis C infection: unraveling the mystery.
    Monsour HP
    Am J Gastroenterol; 1994 Sep; 89(9):1424-6. PubMed ID: 7521571
    [No Abstract]   [Full Text] [Related]  

  • 20. Virological relapse in chronic hepatitis C.
    Poordad FF; Flamm SL
    Antivir Ther; 2009; 14(3):303-13. PubMed ID: 19474464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.